Good
Mostly Aligned
Patient Risk:
Low
Summary
Most claims are directly supported by label language for dosing with or without food (once daily) and for drug interactions emphasizing CYP3A inducers and specific agents (carbamazepine class, rifampin, St. John’s wort). The interaction-related herbal-products claim is only partially supported because the label lists St. John’s wort explicitly rather than all herbal products.
Category Scores
Accurate Statements
Pifeltro (doravirine) can be taken with or without food.
Label 2.1: “one 100 mg tablet taken orally once daily with or without food.”
You do not need to time Pifeltro doses around meals.
Implied by Label 2.1 stating “once daily with or without food.”
Food does not require dose adjustments based on meal timing for Pifeltro.
Label 2.1 provides fixed dosing “with or without food” and no meal-timing-based adjustment is described.
Food does not change the dosing instructions for Pifeltro.
Label 2.1: dosing is “with or without food” (no change in dosing instructions based on food).
Certain seizure medicines can interact with doravirine and affect its levels in the body.
Label 4 + 7.1: anticonvulsants “carbamazepine, oxcarbazepine, phenobarbital, phenytoin” are CYP3A inducers that decrease doravirine plasma concentrations.
Rifampin/rifamycin antibiotics can interact with doravirine and affect its levels in the body.
Label 4 + 7.1: “rifampin, rifapentine” are CYP3A inducers and co-administration is contraindicated due to decreased doravirine plasma concentrations.
The main dosing concern with doravirine is interactions with other medicines that can affect its levels in the body.
Label 4 and 7.1 emphasize contraindication/warnings based on CYP3A inducers decreasing doravirine plasma concentrations; label also includes a warning that drug interactions may lead to loss of therapeutic effect/resistance (5.2).
Unsupported Statements
Some herbal products can interact with doravirine and affect its levels in the body.
Label text provided specifies St. John’s wort as a contraindicated CYP3A inducer (decreases doravirine concentrations), but it does not support a general statement about 'some herbal products' beyond St. John’s wort.
Contradictions
Important Omissions
No mention that co-administration with strong CYP3A inducers is contraindicated (including specific listed drugs) and that rifabutin requires a dosage increase to twice daily (~12 hours apart).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Food-without-timing claims are aligned with label. Interaction claims largely match label (CYP3A inducers, seizure anticonvulsants, rifampin/rifapentine). The only notable overgeneralization is the herbal products claim, which is not explicitly supported for all herbal products (label specifically lists St. John’s wort).
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Overgeneralizes 'herbal products' interactions; label provided explicitly lists only St. John’s wort as an example/contraindicated drug, not all herbal products.
Suggested Improvement
Replace 'Some herbal products' with 'St. John’s wort' (or specify that St. John’s wort is the herbal product identified in the label as contraindicated due to decreased doravirine concentrations).